Trial Profile
A Phase I Trial of Sirolimus or Everolimus or Temsirolimus (mTOR inhibitor) and Vorinostat (Histone Deacetylase Inhibitor) in Patients with Advanced Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 22 Dec 2023
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary) ; Everolimus; Sirolimus; Temsirolimus
- Indications Cancer
- Focus Adverse reactions
- 18 Dec 2023 Planned End Date changed from 18 Aug 2025 to 18 Aug 2026.
- 18 Dec 2023 Planned primary completion date changed from 18 Aug 2025 to 18 Aug 2026.
- 18 Dec 2023 Planned End Date changed from 1 May 2021 to 18 Aug 2025.